Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

NCT04819113

Last updated date
Study Location
Tampere University Vaccine Research Turku
Turku, , 20520, Finland
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningococcal Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
76-104 days
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female infants born at >36 weeks of gestation and who are 3 months of age (≥76 to ≤104 days) at the time of consent (the day of birth is considered day of life 1).

- Participants whose parent(s)/legal guardian(s) is willing and able to comply with scheduled visits, treatment plan, and other study procedures.

- Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

- Participants who are available for the duration of the study and whose parent(s)/legal guardian(s) can be contacted by telephone during study participation.

- Participants whose parent(s)/legal guardian(s) is capable of giving signed informed consent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous anaphylactic reaction to any vaccine or vaccine-related component.


- Bleeding diathesis or condition associated with prolonged bleeding time that would
contraindicate intramuscular injection.


- History of microbiologically proven disease caused by N meningitidis or Neisseria
gonorrhoeae.


- Significant neurological disorder or history of seizure (including simple febrile
seizure).


- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination (no laboratory testing required).


- Family history of congenital or hereditary immunodeficiency.


- Other medical or psychiatric condition, including recent or active suicidal
ideation/behavior, or laboratory abnormality that may increase the risk of study
participation or, in the investigator's judgment, make the participant inappropriate
for the study.


- Major known congenital malformation or serious chronic disorder.


- Previous vaccination with any meningococcal vaccine containing groups A, C, W, or Y.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Meningococcal VaccineStudy to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
NCT04819113
  1. Turku,
  2. Bydgoszcz,
  3. Bydgoszcz,
  4. Krakow,
  5. Lodz,
  6. Siemianowice Slaskie,
  7. Trzebnica,
  8. Tampere, Pirkanmaa
  9. Espoo,
  10. Helsinki,
  11. Helsinki,
  12. Järvenpää,
  13. Santiago de Compostela, A Coruna
ALL GENDERS
76 Days+
years
MULTIPLE SITES
Meningococcal VaccineA Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
NCT04645966
  1. Santiago de Compostela, A Coruna
  2. Badalona, Barcelona
  3. Sant Cugat del Valles, Barcelona
  4. Burgos, Castilla Y LEON
  5. Móstoles, Madrid
  6. L'Eliana, Valencia
  7. Paiporta, Valencia
  8. Almeria,
  9. Madrid,
  10. Madrid,
  11. Madrid,
  12. Madrid,
  13. Malaga,
  14. Sevilla,
  15. Sevilla,
  16. Valencia,
  17. Valencia,
  18. Valencia,
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Meningococcal VaccineMenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
NCT04440163
  1. Ormond Beach, Florida
  2. San Antonio, Texas
  3. Krakow,
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Tempe, Arizona
  7. Banning, California
  8. Madera, California
  9. Paramount, California
  10. Paramount, California
  11. Colorado Springs, Colorado
  12. Cooper City, Florida
  13. Coral Gables, Florida
  14. Jupiter, Florida
  15. Lake Worth, Florida
  16. Miami Lakes, Florida
  17. Miami Lakes, Florida
  18. Miami, Florida
  19. Miami, Florida
  20. Miami, Florida
  21. Oviedo, Florida
  22. Tampa, Florida
  23. Adairsville, Georgia
  24. Chamblee, Georgia
  25. Meridian, Idaho
  26. Nampa, Idaho
  27. Mishawaka, Indiana
  28. South Bend, Indiana
  29. Ankeny, Iowa
  30. West Des Moines, Iowa
  31. El Dorado, Kansas
  32. Newton, Kansas
  33. Lexington, Kentucky
  34. Baton Rouge, Louisiana
  35. Haughton, Louisiana
  36. Saint Louis, Missouri
  37. Elkhorn, Nebraska
  38. Omaha, Nebraska
  39. Binghamton, New York
  40. Salisbury, North Carolina
  41. Wilmington, North Carolina
  42. Winston-Salem, North Carolina
  43. Cleveland, Ohio
  44. Cleveland, Ohio
  45. Dayton, Ohio
  46. Fairfield, Ohio
  47. Norman, Oklahoma
  48. Yukon, Oklahoma
  49. Erie, Pennsylvania
  50. Philadelphia, Pennsylvania
  51. Charleston, South Carolina
  52. Bristol, Tennessee
  53. Bristol, Tennessee
  54. Kingsport, Tennessee
  55. Carrollton, Texas
  56. Plano, Texas
  57. Plano, Texas
  58. Holladay, Utah
  59. Provo, Utah
  60. Salt Lake City, Utah
  61. Salt Lake City, Utah
  62. South Jordan, Utah
  63. Ceske Budejovice,
  64. Hradec Kralove,
  65. Jindrichuv Hradec,
  66. Pardubice,
  67. Praha 6,
  68. Pribram,
  69. Aarhus N,
  70. Balatonfüred,
  71. Debrecen,
  72. Gyula,
  73. Miskolc,
  74. Székesfehérvár,
  75. Krakow,
  76. Leczna,
  77. Siemianowice Slaskie,
  78. Trzebnica,
ALL GENDERS
10 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
Official Title  ICMJE A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
Brief Summary This study will evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a second dose at 12 months of age. Current posology allows for 2 doses of Nimenrix before 6 months of age, where the first dose is administered from 6 weeks onwards with a second dose at least 2 months later, with a booster at 12 months; and in infants from 6 months of age, a single dose at 6 months, with a booster dose at 12 months. This study will provide valuable immunogenicity and safety data for a single dose in healthy infants <6 months of age, followed by the booster at 12 months
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Meningococcal Vaccine
Intervention  ICMJE Biological: Nimenrix
MenACWY-TT vaccine
Study Arms  ICMJE Experimental: Nimenrix
Nimenrix
Intervention: Biological: Nimenrix
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 25, 2021)
150
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 11, 2022
Estimated Primary Completion Date July 11, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female infants born at >36 weeks of gestation and who are 3 months of age (?76 to ?104 days) at the time of consent (the day of birth is considered day of life 1).
  • Participants whose parent(s)/legal guardian(s) is willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
  • Participants who are available for the duration of the study and whose parent(s)/legal guardian(s) can be contacted by telephone during study participation.
  • Participants whose parent(s)/legal guardian(s) is capable of giving signed informed consent.

Exclusion Criteria:

  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  • History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
  • Significant neurological disorder or history of seizure (including simple febrile seizure).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Family history of congenital or hereditary immunodeficiency.
  • Other medical or psychiatric condition, including recent or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Major known congenital malformation or serious chronic disorder.
  • Previous vaccination with any meningococcal vaccine containing groups A, C, W, or Y.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 76 Days to 104 Days   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Finland,   Poland,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04819113
Other Study ID Numbers  ICMJE C0921062
2020-005059-19 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP